Loading…
Eris Lifesciences (ERIS)₹1,262+0.71%Pharmaceuticals
Eris Lifesciences is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 24.6 against a peer median of 36.8, and ROCE of 14.0% against a peer median of 16.0%, and latest-quarter sales growth of 12.6% against a peer median of 19.6%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Granules India | 19,820 | 29.6 | 16.0 | 13.8 | 0.30 | 0.2 | 5,343 | 593 | 22.3 | 59.3 | vs ERIS |
| Caplin Point Laboratories | 19,024 | 28.7 | 25.1 | 20.6 | 0.00 | 0.3 | 2,186 | 651 | 19.6 | 18.5 | vs ERIS |
| Onesource Specialty Pharma | 18,607 | — | 1.0 | −1.1 | 0.26 | 0.0 | 1,423 | −74 | 37.2 | 469.8 | vs ERIS |
| Shilpa Medicare | 18,303 | 61.6 | 10.9 | 9.4 | 0.25 | 0.1 | 1,533 | 243 | 45.1 | 114.9 | vs ERIS |
| Alivus Life Sciences | 18,135 | 30.0 | 24.9 | 19.0 | 0.02 | 0.3 | 2,562 | 566 | 6.3 | 31.1 | vs ERIS |
| Pfizer | 17,905 | 24.4 | 24.0 | 18.0 | 0.02 | 1.9 | 2,522 | 722 | 8.2 | 6.4 | vs ERIS |
| Eris Lifesciences | 17,536 | 24.6 | 14.0 | 18.7 | 0.60 | 0.6 | 3,118 | 651 | 12.6 | 39.5 | — |
| Cohance Lifesciences | 16,992 | 159.6 | 8.1 | 7.1 | 0.10 | 0.0 | 2,275 | 150 | −23.2 | −198.0 | vs ERIS |
| AstraZeneca Pharma India | 16,286 | 96.2 | 29.0 | 23.3 | 0.13 | 0.6 | 2,281 | 187 | 29.8 | −32.2 | vs ERIS |
| CORONA Remedies | 15,541 | 74.9 | 33.0 | 29.5 | 0.22 | 0.4 | 1,403 | 185 | 22.3 | 15.3 | vs ERIS |
| Jubilant Pharmova | 15,359 | 43.7 | 8.9 | 6.6 | 0.51 | 0.5 | 8,307 | 398 | 17.3 | −45.1 | vs ERIS |
| Peer median | 17,905 | 36.8 | 16.0 | 18.0 | 0.22 | 0.3 | 2,281 | 398 | 19.6 | 18.5 |
Listed companies closest to Eris Lifesciences in Pharmaceuticals include Granules India, Caplin Point Laboratories, Onesource Specialty Pharma, Shilpa Medicare, Alivus Life Sciences, Pfizer, Cohance Lifesciences, AstraZeneca Pharma India.
Granules India, with a market cap of ₹19,820 Cr.
Eris Lifesciences trades at a P/E of 24.6; the median of its peer set is 36.8. A P/E above or below the median is a description, not a judgement on value.
Eris Lifesciences' return on capital employed is 14.0%, below the peer median of 16.0%.